Skip to main content

Fiscal Wizard · Single-issue tearsheet

BCAB / Jun 21, 2026 Run #7430

BCAB

BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Composite verdict

F 7.5 / 100
Bearish setup · Accumulation 4 drivers · 6 gates blocking
  • Accumulation/Distribution Line
  • Vortex Signal
  • Aroon Oscillator
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 480th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 14 signals100% Bear
Momentum Bearish 7Mean-reversion Neutral 44

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

13.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Greenblatt EY 0
Return on Assets 0
Free Cash Flow Yield 0

Technicals Bearish

1.3 / 100

Bearish setup leads (Accumulation/Distribution Line, Vortex Signal, Aroon Oscillator); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 7
Vortex Signal 14
Aroon Oscillator 16

Risk Gates

6 blocking 4 caution

6 guards active, 27 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BCAB.